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Abstract
Medical message boards are online resources where users with a particular condition
exchange information, some of which they might not otherwise share with medical
providers. Many of these boards contain many posts and contain patient opinions and
experiences that would be potentially useful to clinicians and researchers. We present
an approach that is able to collect a corpus of medical message board posts, de-identify
the corpus, and extract information on potential adverse drug effects discussed by
users. Using a corpus of posts to breast cancer message boards, we identified drug
event pairs using co-occurrence statistics. We then compared the identified drug event
pairs with adverse effects listed on the package labels of tamoxifen, anastrazole,
exemestane, and letrozole. Of the pairs identified by our system, 75-80% were
documented on the drug labels. Some pairs may represent previously unidentified
adverse drug effects.
Keywords: data mining; information extraction; medical message board; drug adverse
effect
1. Introduction
It is well known that the lay public frequently uses online resources such as message
boards to seek and exchange medical information [1-5]. Users of these resources ask
questions and seek advice about topics that they may be hesitant to discuss with their
health care providers. One such topic is concern about adverse effects experienced
with some medications, especially those prescribed for serious conditions such as
cancer, where patient anxiety may be heightened by the characteristics of the disease

and the long-term exposure to potentially toxic drugs. Although adverse events should
be reported through available channels, such as the Adverse Event Reporting System
(AERS) of the U.S. Food and Drug Administration, many patients do not do so, perhaps
because of ignorance of these channels, embarrassment, perceptions of poor provider
availability, etc. Instead, they often use informal networks such as internet message
boards to report and discuss adverse events. The burgeoning of medical message
boards provides evidence of the frequency of discussions about health-related matters
in society at large, and the boards in turn provide a fertile source of data for identifying
and evaluating the advice, concerns, and opinions that are sought and provided by
message board users. However, these data remain largely untapped by researchers in
medical and healthcare domains.
While there are several studies evaluating discussions in message boards and chat
rooms, these have used qualitative research methods.[6-10] To date, there are no
reports in the medical or social sciences literature that apply text mining methods to
these discussions to identify and analyze reports of adverse drug events. Reasons for
this include the unstructured nature of message board text, the use of nonstandard
abbreviations, a wide variety in the use of syntax and spelling, the temporal relationship
between posts in a single thread, and references within messages to other threads.
Despite the difficulties associated with using message board text, researchers in many
domains, particularly marketing, have successfully applied methods to extract
information from this irregular medium. Glance, et al. [11] have developed a
comprehensive system that crawls message boards and derives several different
metrics about products including how much people discuss them and how much users

seem to like those products. Feldman, et al. [12] have also published a system that
extracts comparisons between different products and the attributes that they are
compared on. Other systems have focused on different forms of web content such as
product reviews in order to extract people’s sentiment about certain products [13;14] or
have relied on the pages produced by Google searches to extract the reputation of a
product [15].
Medical message boards have been examined to a much lesser degree. Malouf,
Davidson, and Sherman [16] applied sentiment analysis to epilepsy blogs in order to
extract patient preferences for different seizure disorder drugs. Although not focused on
online user-generated content, pharmacovigilance researchers have also applied data
mining methods in order to extract signals of possible adverse drug events from
databases such as the AERS [17-19]. Electronic health records have also been
examined to identify similar signals [20] as well as to generate more general biomedical
hypotheses [21]. Though there is a history of data mining in the medical domain, it has
yet to exploit the knowledge that can be derived from online user-generated content.
We present here methods that we used to identify such knowledge, specifically selfreported adverse events that may be associated with four hormonal medications that
are commonly used in the treatment of breast cancer.
2. Methods
In order to address the unique difficulties posed by medical message boards, our
system was structured as illustrated in Figure 1.

Figure 1. Overview of the system architecture. 1) Corpus generation; 2) Removal of
personal identifiers; 3) Construction of controlled vocabulary; 4) Information extraction
In step 1, the system downloaded message post pages from a set of message board
sites and removed content unrelated to the posts from these pages. In step 2, the deidentification module removed personal identifiers (e.g., e-mail addresses, phone
numbers, and usernames) from these posts. In Step 3 we developed the controlled
vocabulary by scraping drug and side effect terms from various databases and websites
using automated scripts in the Scrape Terms process. Afterwards, terms that were not
indicative of a drug or event/symptom were removed by hand in the Curate process. In
step 4, all terms in the controlled vocabulary were identified in our de-identified corpus

and any pair of terms that co-occurred at a statistically significant rate was treated as a
“finding”.
2.1. Step 1: Corpus development.
The breast cancer message board corpus was developed in three steps: message
board identification, download, and anonymization. A collection of breast cancer
message boards was identified by manually searching for large message boards
specifically devoted to breast cancer. A custom-built web crawler, a program to browse
the internet and download pages, was used to download messages from each message
board. Since each board was structured differently, the crawler had to be customized
separately for each site in order to make sure that only message post and index page
links within that board were followed. These saved pages were “cleaned” by extracting
the following fields from each message:


Author (replaced with an anonymous identifier in the anonymization step)



Thread ID (the unique identifier for this message’s thread)



Time Posted



Message Body



Message Subject

This cleaning step was necessary since much of the text on a webpage is unrelated to
the users’ posts. Such extraneous text may include the header, footer, navigation bar,
and Javascript for the page. After preprocessing, only about 48% of the tokens, defined

as strings of characters delimited by whitespace, in the original HTML pages were kept
to generate the corpus. The final corpus contained over 1.1 million messages,
comprising over 100 million words; the average message entry is 99 tokens long, with
standard deviation of 135 tokens. This is because a large proportion of the messages
tend to be very short (1-4 tokens), with a very long tail of increasingly long messages.
The following sites were used to generate the corpus: breastcancer.org, komen.org,
csn.cancer.org, bcsupport.org, healthboards.com, cancercompass.com, webmd.com,
dailystrength.org, revolutionhealth.com, ehealthforum.com, oprah.com. Most messages
from the breast cancer corpus are from breastcancer.org (70%), komen.org (16.5%),
and csn.cancer.org (9.2%). Each of the other sites was responsible for 1% or less of
the total entries. This Zipfian distribution of messages over sites, where a select few
sites contain many messages and a long list of sites contain much fewer, is to be
expected.
2.2. Step 2: Anonymization.
In order to de-identify the messages, we created an anonymizer to remove the following
information:


Email Addresses



Phone Numbers



Uniform Resource Locators (URLs)



Social Security Numbers (SSNs)



Usernames



Proper Names

Email addresses, phone numbers, URLs, and SSNs were easily removed using regular
expressions, a tool used to recognize strings of characters, since these types of
identifying information all have predictable structures. There seemed to be very few
instances of these. However, usernames and proper names were more difficult to
remove since message posts often contain spelling errors, non-standard constructions,
inconsistent capitalization, and a wide variety of nicknames and usernames that would
not be found in list of proper names. We first used the 2008 Stanford Named Entity
Recognizer (NER) [22] trained on a combination of the Conference on Natural
Language Learning (CoNLL) 03, Message Understanding Conference (MUC) 6, MUC-7,
and Automatic Content Extraction (ACE) 08 corpora to find proper names.
The performance of the Stanford NER was evaluated, using the precision, recall, and Fscore metrics:

Precision 

Recall 

Number of names correctly removed by NER
Total number of tokens removed by NER

Number of names correctly removed by NER
Total number of names in the sample

 (Precision * Recall) 
F - score  2

 (Precision  Recall) 

(1)

(2)

(3)

Over a random sample of 500 messages containing 523 names identified by a human
coder, the Stanford NER exhibited mediocre performance, achieving precision of 69.6%,

recall of 77.6%, and an F-score of 73.4%. This is likely due to the fact that it was not
trained on message board text and relied on features that may be indicative of proper
names in less noisy text, but not in message board text (e.g., capitalization). In
addition, the Stanford NER was not designed to identify usernames, which could be
very different from proper names. Thus, we had to design and implement our own
system to remove both proper names and usernames [23].
To do so, we trained a conditional random field (CRF) over a 1000 message sample
from the breast cancer corpus consisting of 91,344 tokens, of which 822 were proper
names and 682 were usernames. Proper names and usernames were manually
identified and tagged by a human coder in order to form this training set. Each token
was described by a feature vector. Some examples of features in this vector were
whether the token belonged to a particular dictionary (e.g., proper names, common
English words, and very common English words), whether the token matched a
username in this thread, the position of the token in the message, and the case of the
token. The features for the previous and following two tokens were also included in
each token’s feature vector.
To remove proper names and usernames from a particular message, we tokenized the
message and ran the CRF over the feature vectors for these tokens. These vectors
included features that are useful to named entity recognition across domains (e.g., is
the token title case, does it belong to a list of names, is it a possible misspelling of a
name) as well as features that take advantage of the structure of message boards and
message board posts (e.g., does the token often occur near the beginning or end of
posts, does the token have a high tf-idf value out of all tokens in a particular message

board when treating entire message boards as documents). Any token with a predicted
probability of being a name greater than 0.05 was replaced with an anonymous tag.
This 0.05 threshold was chosen in order to maximize the recall of the anonymizer
without removing too many non-name tokens. Testing this system over a 500 message
sample from the breast cancer corpus containing 483 total names yielded a precision of
69.6%, recall of 98.1%, and F-score of 81.4% for removing names. Our anonymizer
demonstrates precision comparable to the Stanford NER’s, a much higher recall (98.1%
compared to 77.6%), and is designed to remove usernames as well. A sample
message from the de-identified corpus is provided below:
<message> <body>This is a terrrific radio interview with <name></name> <name></name> whose article I referenced
in the topic about cancer not being a disease. I am convinced with all the research I've done about the liver, and what
Dr. <name></name> recommends also, this could be the answer to the cause of all imbalance. Years ago, my father
was told that the liver was the clue to all disease by a great Dr. he went to. I am doing this cleanse next, since I just
finished the colon cleanse. Any thoughts after listening to this broadcast would be appreciated.
<url_body></url_body> Here are flush recipies: <url_body></url_body></body>
<author>AUTHOR‐79_701725‐0</author>
<url>http://community.breastcancer.org/forum/</url>
<condition>breast cancer</condition>
<thread_id>79_701725</thread_id>
<time>Mar 7, 2008 11:31 am</time>
<subject>liver and gall bladder flush</subject> </message>

Block 1. Sample message after anonymization. The message was altered to prevent
searching on the Internet for its original posting and subsequent identification of the
poster.
2.3. Step 3: Controlled vocabulary.
As mentioned above, patients posting on medical message boards often use lay
vocabulary to describe the symptoms they are experiencing or the medicines they are
taking. In order to extract useful information from these posts, a controlled vocabulary

of lay medical terms was constructed. Websites and databases containing lists of
dietary supplements, pharmaceuticals, and adverse events were scraped for terms to
populate the vocabulary. Since most of these lists of terms had a regular structure, we
were able to collect the terms using simple scripts, which were programmed, for
example, to save all terms that occur in a particular field of a database or in a particular
list on a webpage. Terms that were likely to result in false positives (e.g., event: boil,
shake) were manually removed from the vocabulary. The medical vocabulary consisted
of the following:


Dietary supplements: hand-compiled by one of the authors (JM), who has
expertise in complementary and alternative medicine: 507 terms



Pharmaceuticals: Cerner Multum Drug Lexicon, (Denver, CO): 16,383 terms



Events (terms that could either refer to an indication for a drug or an adverse
event caused by a drug): http://www.medicinenet.com/ and adverse events listed
in the AERS database over the period 2004 through the second quarter of 2009;
not specific to breast cancer: 26,817 terms

We then augmented all of these lists using the Consumer Health Vocabulary (CHV)
provided by the Consumer Health Vocabulary Initiative1, in order to produce a
vocabulary closer to the lay vocabulary that would be used by patients on a discussion
board. This also provided us with a way of classifying several different terms as being
instances of a more general term (e.g., turmeric, tumeric [sic], and curcumin are three
different ways that a user may refer to curcumin).
1

http://www.consumerhealthvocab.org/

2.4. Step 4: Information Extraction.
After the anonymized corpus and controlled vocabularies were generated, we
generated frequency counts of each vocabulary term in the corpus, in order to establish
which terms are talked about the most. This is similar to the Buzz count used in Glance,
et al. [11]. We retrieved the single term counts by counting the number of messages in
which each term occurred. Each token was first stemmed using a Porter stemmer, an
algorithm meant to remove inflection from a word, from the Natural Language Toolkit
(NLTK) [24] before matching it to a term in the controlled vocabulary.
We also extracted association rules between pairs of terms. By association rules we
mean pairs of terms that co-occur within 20 tokens more frequently than would be
expected if the terms were distributed independently. These rules have no causal
direction, but simply suggest that there is a correlation between the presence of one
term and the presence of the other. In order to generate all possible association rules
between terms, all terms in the controlled vocabulary occurring in the corpus were
identified. Any two terms co-occurring within a window of 20 tokens apart were treated
as a possible association rule; this window seemed to produce the best precision and
recall of valid association rules over a random sample of 500 messages.
Our approach of relying on co-occurrences of terms to generate association rules has
been used in several other systems [12;15;16;20;25]. For each association rule (X, Y)
output by the query script, we constructed a 2 by 2 table of the occurrence of X and Y
and calculated a one-tailed Fisher’s exact P-value for that rule, expressing the likelihood
that these two terms co-occurred independently by chance. All association rules with p-

values greater than the Simes-corrected [26] 0.05 threshold were then determined to be
non-significant. However, rules with very low counts were not ignored only because
they were infrequent; these low count pairs could potentially signal a rare, but very real
relationship between the two terms.
3. Results
3.1 Validating the system
In order to validate our system, we selected four of the most commonly used drugs to
treat breast cancer: tamoxifen (Nolvadex), anastrazole (Arimidex), letrozole (Femara),
and exemestane (Aromasin). Tamoxifen has long been the standard treatment for
hormonally-responsive breast cancer. Anastrazole, letrozole, and exemestane are
aromatase inhibitors, more recently developed, that are also used to treat hormonallyresponsive breast cancer. We chose these four drugs because they have similar
indications and were frequently mentioned in the breast cancer corpus. Table 1 shows
the top 10 association rules by count identified by our system for tamoxifen.
Drug-

Drug-

Drug+

Drug+

/Event-

/Event+

/Event-

/Event+

Event

P-Value

hot flashes

1,186,668

10,809

30,306

1,949

0

breast cancer

1,135,252

62,225

30,914

1,341

1

menopause

1,189,938

7,539

31,236

1,019

0

pain

1,114,656

82,821

31,547

708

1

weight gain

1,193,000

4,477

31,751

504

4.47E-143

joint pain

1,192,247

5,230

31,780

475

3.12E-104

uterine cancer

1,196,619

858

31,881

374

6.03E-276

fatigue

1,182,660

14,817

31,973

282

1

night sweat

1,195,587

1,890

31,981

274

1.40E-100

depression

1,191,644

5,833

32,001

254

1.53E-12

weight loss

1,193,207

4,270

32,055

200

9.69E-13

Table 1. Top ten rules returned for tamoxifen ranked by count. Drug+/Event+ is the
number of messages that contain the drug and event co-occurring within a 20 token
window, Drug+/Event- is the number of messages containing only the drug and not the
event, Drug-/Event+ is the number of messages containing only the event and not the
drug, and Drug-/Event- is the number of messages mentioning neither the drug nor the
event. P-values in this list are very close to 0 or 1.
For each of these four drugs, we compiled a documented list of all adverse events
(AEs) believed to occur from the drug. This list was compiled from all of the AEs
mentioned in tables and notes contained in the drug label.
For each of the four drugs, we compiled a list of significantly associated events returned
by our system. We then evaluated our system’s performance by comparing our system
list against the documented list for that particular drug using the precision and recall
metrics. In this context, precision was defined as the proportion of the events we found
that occur in the documented list as AEs:

Precision 

# AEs in both the documented list and the system list
# AEs in the system list

(4)

Recall was defined as the proportion of documented AEs occurring in the system list:

Recall 

# AEs in both the documented list and the system list
# AEs in the documented list

(5)

This method of evaluation is similar to that used to evaluate a pharmacovigilance
system over electronic health records by Wang, et al. [20].

Recall
Value
tamoxifen

Precision
N

Value

N

42.4%

66

79.1%

62

36.8%

76

75.0%

55

(Aromasin) 25.0%

64

75.8%

33

35.6%

59

78.0%

41

35.1%

265

77.0%

191

anastrazole
(Arimidex)
exemestane

letrozole
(Femara)
All four
drugs

Table 2. Recall refers to the proportion of terms in the documented list that matched
terms in the system list, over the total number of terms in the documented list.
Precision refers to the proportion of terms in the system list that matched terms in the

documented list over the total number of terms in the system list. ‘N’ refers to the size
of the denominator for each value calculated.
3.2. Identifying rare and novel events
In addition to evaluating our system for its ability to identify many of the AEs listed on
the drug label, we also investigated the events returned by our system that were either
documented as rare AEs or were not listed on the drug label at all. For example, our
system identified many AEs that were documented as rare events for tamoxifen; these
included “fatty liver”, “uterine cancer”, “stroke”, and “pulmonary embolism”. We referred
back to the messages where the terms occurred in order to determine the context in
which authors mentioned these events. A few anecdotes from these messages are
listed below. Note that the majority of message board users referred to the aromatase
inhibitors by their brand names and these anecdotes reflect that.

I saw the liver specialist ‐‐ was able to get in earlier and he said my fatty liver is probably from taking Tamoxifen.
I am still very scared, because Tamoxifen can cause uterine cancer.
had a stroke recently, after finishing 5 yrs of Tamoxifen. This sealed my decision.
I was one of the few that developed a pulmonary embolism while on Tamoxifen ‐ lucky me.

Block 2. Anecdotes of rare (as defined by label) AEs occurring with Tamoxifen. Very
few authors mentioned that they developed uterine cancer, and that they were simply
scared of developing it. For the other rare events, authors had mentioned that they
actually experienced these AEs.
Although it is mentioned as a very rare AE on the label, “uterine cancer” co-occurred
374 times with tamoxifen in our breast cancer corpus. This does not necessarily

suggest that it is a more common AE than the label states, but simply that people
frequently talk about it. Most of these messages demonstrated anxiety about taking
tamoxifen because of this side effect, rather than having actually developed uterine
cancer. However, for other AEs, such as “pulmonary embolism” and “fatty liver”, authors
mentioned that they had actually developed the conditions.
There were a few AEs that were reported with one of these four drugs that were not
listed on the drug label. Many of these were false positives (i.e., AE and drug mentions
were unrelated in the posts, determined by human). However, there were a few
significantly associated events (with p-value less than Simes-corrected .05) that
message board authors claimed to have actually occurred. The following
undocumented AEs were found to be based on instances where message board
authors claimed to have actually experienced the AE.
 tamoxifen: weight gain
 anastrazole: chapped lips, dry eye, lupus, conjunctivitis, fibromyalgia
 exemestane: dry eye, high cholesterol, vaginal dryness
 letrozole: mood swings, vaginal discharge
Not all of these AEs may be truly caused by the drug, but, at the very least, they may
give practitioners a better idea of common perceptions that patients hold about these
drugs. A few examples of posts where authors mentioned experiencing these AEs are
listed below in Block 3.

The only SEs i had on Tamoxifen were weight gain and hot flashes/night sweats.
Has anybody been suffering from chapped, cracked lips, especially at the corners of your mouth, since being on
Arimidex? I had this problem many years ago but always could fix it by taking vitamin B complex. The vitamin B
complex isn’t helping any more and I am wondering if Arimidex is causing this.
My eye doctor says my dry eyes are probably from age ‐‐‐ but he thinks Arimidex made them worse and sent a letter
to my DR. saying so.
2/07 Moved to Aromasin & Zometa because of Arimidex triggering RA & Lupus
I've also had conjunctivitis 4 times. My onc said this wasn't a SE of arimidex but I know it is!
I’m now on arimidex. I am doing fine with BC but have developed fibromyalgia.
After about 1.5 years on Aromasin, my cholesterol which is normally 186 was at 254. Something I have not noticed
anyone talking about is high cholesterol.
oh, should add.....rather significant impact....of aromasin ‐ was vaginal dryness.
I am on aromasin and have developed dry eyes. does anyone else have this problem?
slammed back with flushings, terrible night sweats, bad mood swings, now have bad joint pain(mostly in my ankle
and right hand/thumb). oh ugh with the femara!
Is there a side effect, that is B9, from Femara that causes vaginal discharge? I just got home from a cruise to AK and
upon wake up this a,.m. [sic] I had a discharge. Not real bloody but kind of like the very last day of a light period.

Block 3. Sample anecdotes of undocumented AEs that message board authors claimed
to have experienced from tamoxifen, anastrazole, exemestane, and letrozole.
4. Discussion
4.1 Contributions to low recall
Our system results in relatively low recall of drug AEs documented on the label, which
seems particularly striking for more common side effects, given that these AEs are very
common and one would expect authors to mention these symptoms frequently in their
posts. However, many of these common AEs are mentioned very frequently throughout
the entire corpus. One example is fatigue, a known AE of anastrazole, but also a
potential effect of cancer itself. The terms “fatigue” and “arimidex” co-occurred 210

times within the breast cancer corpus. However, each of these terms occurred in
15,099 and 17,124 messages, respectively, yielding a non-significant p-value. In order
for the association rule “arimidex-fatigue” to be significant, these two terms would have
had to co-occur at a much higher frequency than what was observed. Our system
seems better suited to finding rare AEs that are related to a specific drug, such as
“uterine cancer” for “tamoxifen”. However, identifying new adverse events is probably a
more appropriate goal than measuring the frequency of known side effects.
It is also important to note that multiple event terms returned by our system may match
just a single AE in the documented AE list. For example, if the documented AE list
contained “pain in extremity”, then the terms “finger pain” and “toe pain” in the system’s
returned list would be considered members of the documented AE list. This also
contributes to our system’s low recall.
The low recall against the documented list is due mostly to the fact that the documented
list is long. Some of the terms in this list are pervasive within posts (e.g., fatigue,
nausea, pain), and do not co-occur frequently enough with the specific drug to suggest
a significant association rule. However, other AEs in the documented list are never
mentioned by authors at all. Some examples of terms that are absent from our breast
cancer corpus but are documented AEs for one or more of the four drugs we
investigated are “increased bilirubin”, “increased creatinine”, “thrombocytopenia”,
“increased alkaline phosphate”, and “stevens-johnson syndrome”. Many of these are
laboratory abnormalities that might not be noticed or known by patients.
4.2 Undocumented events returned by system

Our system exhibited relatively high precision in the AEs that it returned. However, on
average, 23% of the drug-event rules identified by our system were undocumented on
the label. Some of these undocumented AEs appeared to be unrelated to the drug.
These events tended to co-occur with the drug very infrequently (generally less than 10
times), and occur very infrequently throughout the corpus. Because the number of cooccurrences between the drug and event was so small, it was simple for us to refer
directly to the messages where these terms co-occurred and determine whether the
author reported the event as being an AE of the drug.
Some pairs that our system identified were considered to be false positives since they
were not specifically documented as, but were similar to, AEs on the drug label.
“arimidex-gout” was one of these pairs. Although gout is not a documented AE of
anastrazole, it is a case of acute arthritis. The messages that mentioned this event
noted remedies for gout that may be effective in treating aromatase inhibitor-induced
arthritis. “Menopause” is an event that was returned by all four drugs. Authors used the
term “menopause” to describe the AEs that they were experiencing as menopausal,
particularly hot flashes; they did not specifically claim that a particular drug had induced
menopause.
Our system does not determine the kind of relationship (indication or side effect)
between the drug and event for each association rule. Rather, it suggests only that the
drug and event terms are correlated. For example, the events “bone density
decreased”, “bone loss”, and “osteoporosis” were all significantly associated with
tamoxifen. However, tamoxifen is known to increase bone density [27]. Referring back
to the original messages where these event terms and “tamoxifen” co-occurred revealed

that post authors were glad that tamoxifen prevented or remedied these events. Some
terms were actually contraindications for the drug, such as “Factor V Leiden mutation”
(associated with an increased risk of blood clots) for tamoxifen. Even though these
terms were related to the drug, are not caused by the drugs and were thus treated as
false positives.
The remainder of the undocumented events consisted of messages where the author
claimed to have experienced the AE in response to the drug. Block 3 contains several
examples of these undocumented AEs. Some of these AEs may be common
knowledge in the medical community even though they are not listed on the label. For
example, it is known that tamoxifen tends to make it more difficult for patients to lose
weight [28] even though neither “weight gain” nor “difficulty to lose weight” is mentioned
as an AE on the tamoxifen label. Other AEs mentioned in the corpus may not be
commonly accepted as an AE of that particular drug. Controlled studies would be
needed to verify that these undocumented AEs actually occur from a particular drug.
However, these anecdotes may serve as signals that could be rigorously verified in
controlled studies.
4.3 Further work
We understand that medical message board corpora are very different from clinical trial
data, health care data, and databases of reported adverse events. Medical message
boards provide a community and support for their members. Post authors not only
communicate how they are feeling and any AEs they have experienced, but also AEs
that they are worried about or that a friend may have claimed to experience. However,

given that we have shown that it is able to reliably extract known AEs for several drugs,
it may have potential utility for identifying undocumented AEs for dietary supplements
that breast cancer patients use as well.
Extending the system to determine the relation between the drug and event, for
example, indication or AE, would be useful for other drugs as well as nutritional
supplements and herbal preparations. We will also improve our system to extract other
types of information from medical message boards. Currently our system is able to
identify documented AEs of drugs with high precision by the frequency that they cooccur. However, the current system cannot determine what type of speech act the
author used for each specific case where they co-occurred. For example, the author
could be claiming that they actually experienced the AE, claiming that their friend
experienced the AE, wondering if a drug causes that particular AE, or are just worried
about a specific AE. Refining this system to identify these speech acts would enable
our system to be used as an alternative to focus groups. Another possible route of
exploration would be to extend our system to identify instances of drug non-adherence,
and identify the AEs that led to this decision.
It would be interesting to know how people generally feel about a particular drug, based
on their posts on message boards. Do they like a drug? Do they hate it? Why?
Extending our system to perform a sentiment analysis on the breast cancer corpus
would allow researchers and medical practitioners to get a sense of what people think
about certain drugs.

We also intend to apply our system to medical message board corpora for conditions
other than breast cancer, in order to evaluate its ability to generalize to other conditions.
Currently we have compiled corpora of obesity, diabetes, and arthritis message board
posts. These are ideal candidates for our method since they contain a large number of
messages because they are all chronic conditions with a high prevalence. We expect
similar results to those generated from the breast cancer corpus. In addition, we will
continue to update the system’s controlled vocabulary based on how well it identifies
relevant instances of drug and event mentions.
6. Conclusion
We have designed a system to identify signals of potential adverse events that
overcomes many of the difficulties associated with medical message boards and is able
to extract useful information from them. Our system is able to generate a corpus of
medical message board text by downloading the message pages, extracting the
relevant fields from the pages, and programmatically removing identifying information
from the documents. These de-identified documents are then searched for terms
occurring in the controlled vocabulary in order to extract association rules that may
signify meaningful relationships between these terms.
We demonstrated the efficacy of this system by extracting the significant drug-event
association rules for four hormonal breast cancer treatment drugs from a corpus of
breast cancer message board posts and compared this list to a list of all AEs that were
documented on each drug label. Although our system’s recall over these documented
AE lists was relatively low (average of 35.1%), the precision was relatively high

(average of 77.0%), suggesting that the terms in the significant association rules
returned are not only correlated, but represent a real semantic relationship as well.
In addition, we identified that some of the undocumented AEs considered significant by
our system signaled an AE that message board authors claimed to have experienced
from the drug. Whether or not the AE was actually caused by the drug is unknown.
However, it may signal a true AE from that drug, and may be worth further investigation.
Even if the AE is not caused by the drug, it is useful to know what symptoms patients
believe (correctly or not) are being caused by the drug.
In future work, we plan to extend the system to identify the speech act that was used for
each drug-side effect mention and to use this system to identify undocumented adverse
effects from dietary supplements.
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